摘要
目的:观察类风湿性关节炎(简称RA)并肝功能异常患者使用反应停的疗效及安全性。方法:6例RA合并肝功能异常的患者使用反应停平均150mg/d,治疗1年,以7项临床指标(关节肿胀指数、关节压痛指数、休息痛、晨僵时间、握力、血沉、C反应蛋白)为主要疗效指数,观察治疗前后肝功能的变化。结果:6例患者7项指标均显著改善,不良反应少,而且较轻,治疗过程中2个月复查1次肝功能无明显变化。结论:反应停对RA并肝功能异常患者是一个很有前途的药物,其生物学作用机制可能与炎症因子TNF-α基因表达受抑制有关。
Objective：To observe the curetive effect and safety of thalidomide in the treatment of rheumatoid arthritis （RA） with liver function abnormality.Methods：Six patients with rheumatoid arthritis and liver function impairment were treated with thalidomide in a dose of 150 mg/d for a year.Seven indices were measured as primary effect exponents,and the change of liver function before and after treatment was observed respectively.Results：All seven indices in 6 cases were improved,with less and well-tolerated side-effect.Each patient received a follow-up examination of live function every two months during the treatment,and there was no obvious change in their liver function.Conclusion：Thalidomide is a reasonably promising drug for treating rheumatoid arthritis with liver function abnormality,and its biological mechanism of action is possiblely related to the gene expression of proinflammatory cytokine TNF-α by suppression.
出处
《现代医药卫生》
2005年第22期3052-3053,共2页
Journal of Modern Medicine & Health
关键词
类风湿性关节炎
肝功能损害
反应停
Rheumatoid arthritis
Liver function impairment
Thalidomide
